



Hybrid Event

# International Symposium on Targeting Homologous Recombination Deficiency in Cancer

From Bench to Clinic 2025

26-27 **06** 2025  
Conference Venue **BRFAA**

BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, GREECE

## Scientific Program


Secretariat



Scientific | Cultural Events & Publications

T +30 210 7240039 F +30 210 7240139

E info@scep.gr www.scep.gr



Organized by



## Welcome letter

Dear Friends and Colleagues,

It is our great pleasure to welcome you to the **International Symposium on Homologous Recombination and DNA Repair: From Bench to Clinic 2025**, taking place on **June 26–27, 2025**, at the **Biomedical Research Foundation of the Academy of Athens**.

This symposium will bring together speakers from Greece and abroad, covering a wide range of expertise, including clinical and laboratory medicine, basic science, diagnostics, and the private sector. The event will explore fundamental aspects of **DNA repair, with a focus on homologous recombination**, molecular tools for identifying tumours with DNA repair deficiencies, and the latest clinical advancements in the field.

Key topics include:

- **Basic biology of DNA damage response**, with an emphasis on homologous recombination
- **Development of inhibitors leveraging synthetic lethality**
- **Current and emerging methodologies** for detecting homologous recombination deficiency for patient stratification
- **Clinical applications** of DNA repair inhibitors, alone or in combination with other therapies, across various tumour types.

We warmly welcome scientists, clinicians, students, and healthcare professionals interested in DNA repair to join us for this exciting event.

Warm regards,

The Organizing Committee

**Pr. A. Klinakis**  
 PhD, Biochemical Research  
 Foundation Academy of Athens  
 (BRFAA), GR

**Dr. P. Constantoulakis**  
 PhD, GENOTYPOS MSA,  
 Athens, GR

**Pr. W. Niedzwiedz**  
 PhD, The Institute of  
 Cancer Research,  
 London, UK

**Dr. J. Loizou**  
 PhD, The Institute of  
 Cancer Research,  
 London, UK

**Dr. S. Linardopoulos**  
 PhD, Oncology AstraZeneca,  
 Cambridge, UK

## Thursday, June 26, 2025

08.00-08.15: **Registration**

08.15-08.30: **Welcome address**

**A. Klinakis (GR)**

08.30-10.10: **Basic Research Session (I)**

Chairs: **A. Klinakis (GR), Th. Rampias (GR)**

08.30-08.50: DNA resection, ssDNA gaps and PARP inhibitor sensitivity:  
 Mechanisms and therapeutic opportunities **W. Niedzwiedz (UK)**

08.50-09.10: DNA damage and innate immune responses in  
 health and disease **G. Garinis (GR)**

09.10-09.30: Beyond BRCA: why PARP inhibitors also  
 kill ATM-deficient cancer cells **R. Chapman (UK)**

09.30-09.50: Immune TME landscape of HRD tumors and their dynamics  
 during cancer evolution **D. Dangaj (CH)**

09.50-10.10: Discussion

10.10-10.40: **Invited Lecture**

Chair: **V. Georgoulis (GR)**

Germline and Somatic mutation rate **S. Antonarakis (CH)**

10.40-11.00: **Coffee break**

11.00-12.50: **Methodologies and Diagnostics Session**

Chairs: **P. Constantoulakis (GR), G. Nasioulas (GR)**

11.00-11.20: How do you assess homologous recombination  
 (validated clinically) **G. Christopoulou (GR)**

11.20-11.40: Technical aspects and clinical applications of HRD  
 testing based on AmoyDx pipelines  
 (Molecular Pathologist perspectives) **U. Malapelle (IT)**

11.40-12.00: Utilizing Pillar Biosciences' Rapid oncoReveal 4-Gene  
 Methylation Panel to guide the expanded use of  
 PARPi therapy in breast cancer patients **E. Christoforou (UK)**

12.00-12.20: HRD Testing in Ovarian Cancer: A Molecular  
 Pathologist's Perspective **E. Guerini Rocco (IT)**

12.20-12.40: Validating and Selecting the Optimal HRD Assay within  
 a Comprehensive Genomic Profiling (CGP) Panel? **E. Papadopoulou (GR)**

12.40-12.50: Discussion

**12.50-13.20: Keynote Lecture**

Chair: **J. Loizou (UK)**

Genome organization in DNA repair pathway choice and mutagenesis

**E. Soutoglou (UK)**

**13.20-14.30: Light Lunch**

**14.30-16.20: Basic Research Session (II)**

Chairs: **W. Niedzwiedz (UK), V. Anastasopoulou (GR)**

14.30-14.50: Mechanisms of sensitivity of cancer cells to ATR and CHK1 inhibitors

**Th. Halazonetis (CH)**

14.50-15.10: Signaling replication stress and DNA damage beyond cell boundaries

**Ph. Pasero (FR)**

15.10-15.30: Epigenetic regulation of DDR

**A. Klinakis (GR)**

15.30-15.50: Inherited DNA repair deficiencies

**G. Stewart (UK)**

15.50-16.10: Replication stress of CNV in HRD tumors

**Th. Rampias (GR)**

16.10-16.20: Discussion

**Friday, June 27, 2025**

**08.30-10.00: PARP inhibitors in clinic: Clinical state of the art**

Chair: **V. Georgoulis (GR)**

08.30-08.50: Updating the therapeutic use of PARPi in ovarian cancer

**R. Zakopoulou (GR)**

08.50-09.10: Updating the therapeutic use of PARPi in breast cancer

**E. Fountzila (GR)**

09.10-09.30: Updating the therapeutic use of PARPi in prostate cancer

**M. Lontos (GR)**

09.30-09.50: Is agnostic treatment of HRD/GSS-positive tumors with PARPi a therapeutic step forward?

**V. Anastasopoulou (GR)**

09.50-10.00: Discussion

**10.00-11.10: Biology: Resistance to PARPi**

Chairs: **Th. Rampias (GR), P. Constantoulakis (GR)**

10.00-10.20: Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy

**J. Loizou (UK)**

10.20-10.40: ATR inhibitor-based combinations to overcome PARP inhibitor resistance

**I. Gounaris (DE)**

10.40-11.00: AI Biomarkers of Genomic Instability in Triple Negative Breast Cancer

**S.J. Sammut (UK)**

11.00-11.10: Discussion

**11.10-11.30: Coffee Break**

**11.30-13.00: Early clinical trials Session**

Chairs: **S. Linardopoulos (UK), P. Constantoulakis (GR)**

11.30-11.50: Homologous recombination status of platinum responsive advanced triple negative breast cancers treated with olaparib +/- Durvalumab maintenance therapy (Clinical perspective)

**T. Tan (US)**

11.50-12.10: Discovery and preclinical characterisation of saruparib (AZD5305), a PARP1-selective inhibitor and trapper

**M. Albertella (UK)**

12.10-12.30: First-in-human Phase 1/2a trial of the first-in-class new PARP1 inhibitor saruparib in patients with advanced solid tumours with HRR mutations

**S. Linardopoulos (UK)**

12.30-12.50: Tuvusertib (ATR inhibitor) in combination with niraparib or lartesertib (ATM inhibitor): initial safety and efficacy from Ph1b studies

**I. Gounaris (DE)**

12.50-13.00: Discussion



13.00-14.00: **Light Lunch**

14.00-15.10: **Basic Research Session**

Chairs: **A. Klinakis (GR), Th. Rampias (GR)**

14.00-14.20: Ovarian cancer testing in the UK-a genomics perspective **G. Burghel (UK)**

14.20-14.40: Telomeric instability in homologous recombination deficiency  
and cancer **S. Gagos (GR)**

14.40-15.00: The evolution of combinatorial treatment with PARPi **M. Sideridou (GR)**

15.00-15.10: Discussion

15.10: **Closing remarks**



## Faculty

**Albertella M.** D Phil, Senior Director, Bioscience, AstraZeneca Oncology R&D, Cambridge, UK

**Anastasopoulou V.** Postdoctoral Researcher, Hellenic Oncology Research Group, Athens, Greece

**Antonarakis S.** Professor Emeritus, University of Geneva Medical School, Switzerland / MediGenome, Swiss Institute of Genomic Medicine, Geneva, Switzerland

**Burghel G.** Consultant Clinical Scientist, North West Genomic Laboratory Hub) / Honorary Senior Lecturer, University of Manchester, UK

**Chapman R.** MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK

**Christoforou E.** Senior Scientist, AstraZeneca, Early Oncology R&D, Translational Medicine Epigenomics, UK

**Christopoulou G.** MSc, PhD, Lab Director, Head of Genetics & Genomics Dpt, Genotypos S.A.

**Constantoulakis P.** PhD, Scientific Director, Genotypos MSA, Greece

**Dangaj D.** PhD, Privat Docent (Lecturer), Group Leader, Laboratory Tumor Microenvironment and Biomarker Discovery, Department of oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, Switzerland

**Fountzila E.** Medical Oncologist, Clinical Associate Professor, European University Cyprus, St Lukes Hospital, Thessaloniki, Greece

**Gagos S.** Principal Investigator Biomedical Research Foundation of the Academy of Athens (BRFAA), Greece

**Garinis G.** Professor of Genetics, Department of Biology, University of Crete, Affiliated Group leader at IMBB-FORTH, Greece

**Georgoulis V.** Emeritus Professor of Medical Oncology, School of Medicine, University of Crete, Greece

**Gounaris I.** MD, PhD, VP, Head of Clinical Development DNA Damage Response (DDR), Merck KGaA

**Guerini Rocco E.** Associate Professor of Pathology, Department of Oncology and Hemato-Oncology, University of Milan, and Chair of Molecular Pathology Unit, Division of Pathology, European Institute of Oncology, IRCCS, Milano, Italy

**Halazonetis Th.** Professor, Dept of Molecular and Cellular Biology, University of Geneva, Switzerland

**Klinakis A.** PhD, Investigator - Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece



# International Symposium on Targeting Homologous Recombination Deficiency in Cancer

26-27 June 2025 | Conference Venue BRFAA

BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, GREECE

From Bench to Clinic 2025

**Linardopoulos S.** Director, Translational Science, Oncology AstraZeneca, Cambridge, UK

**Liontos M.** Assistant Professor, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece

**Loizou J.** Group Leader Divisions of Cancer Therapeutics and Breast Cancer Research | Deputy Director Centre for Target Validation, The Institute of Cancer Research, UK

**Malapelle U.** Associate Professor in School of Medicine, Chair of Predictive Molecular Pathology Laboratory, Department of Public Health of University Federico II of Naples, Naples, Italy

**Nasioulas G.** PhD, Chief Scientific Officer, Genekor Medical S.A. Greece

**Niedzwiedz W.** Professor, PhD, Genome Instability and Cancer Team, The Institute of Cancer Research, London, UK

**Papadopoulou E.** PhD, International Laboratory Director, Genekor Medical S.A., Greece

**Pasero Ph.** Institute of Human Genetics, CNRS and University of Montpellier, France

**Rampias Th.** PhD, Investigator - Assistant Professor Level, Biochemical Research Foundation Academy of Athens (BRFAA), Greece

**Sammut S.J.** MD, PhD, Group Leader, Cancer Dynamics Lab, Consultant Medical Oncologist, The Royal Marsden Hospital, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, Chester Beatty Laboratories, London, UK

**Sideridou M.** Postdoc Researcher, Biochemical Research Foundation Academy of Athens (BRFAA), Greece

**Soutoglou E.** Professor of Genome Stability, Genome Damage and Stability Centre, Sussex University, School of Life Sciences, University of Sussex, Brighton, UK

**Stewart G.** Professor, Department of Cancer and Genomic Sciences, University of Birmingham, UK

**Tan T.** Senior Consultant Medical Oncologist, National Cancer Centre Singapore

**Zakopoulou R.** MD, PhD, Medical Oncologist, Locum Consultant, General Anticancer Hospital "Agioi Anargyroi", Athens, Greece



# International Symposium on Targeting Homologous Recombination Deficiency in Cancer

26-27 June 2025 | Conference Venue BRFAA

BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS, GREECE

From Bench to Clinic 2025

## Info

### Organized by



Hellenic Oncology Research Group

### Date

26-27 June, 2025

### Venue

The Biomedical Research Foundation of the Academy of Athens (BRFAA)  
4, Soranou Efessiou Str., Hologargos

### Hybrid Event

You can watch the Hybrid Event online through the link [www.livetime.gr](http://www.livetime.gr) and ask written questions throughout the presentations

### Registration

Free

### Certificate of Attendance

The certificate of attendance will be given to the participants at the end of the event.

### Secretariat SCEP\*

Scientific | Cultural Events and Publications

**T** +30 210 7240039 **E** [info@scep.gr](mailto:info@scep.gr)

[www.scep.gr](http://www.scep.gr)   



Γραμματεία  


Scientific | Cultural Events & Publications

**T** +30 210 7240039 **F** +30 210 7240139

**E** [info@scep.gr](mailto:info@scep.gr) [www.scep.gr](http://www.scep.gr)

